Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
Company Research
Source: GlobeNewswire
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company’s American Depositary Shares (ADSs), signaling their confidence in the company’s growth and direction. On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. These insider purchases reflect the leadership’s strong confidence in Quoin’s growth trajectory and commitment to delivering long-term value to shareholders as the company advances its mission to address
Show less
Read more
Impact Snapshot
Event Time:
QNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNRX alerts
High impacting Quoin Pharmaceuticals, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
QNRX
News
- Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome PatientGlobeNewswire
- Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024GlobeNewswire
- Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals announces insider share purchases [Seeking Alpha]Seeking Alpha
QNRX
Sec Filings
- 11/8/24 - Form 424B3
- 11/8/24 - Form 8-K
- 11/8/24 - Form 10-Q
- QNRX's page on the SEC website